CA2258920A1 - Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies - Google Patents

Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies

Info

Publication number
CA2258920A1
CA2258920A1 CA002258920A CA2258920A CA2258920A1 CA 2258920 A1 CA2258920 A1 CA 2258920A1 CA 002258920 A CA002258920 A CA 002258920A CA 2258920 A CA2258920 A CA 2258920A CA 2258920 A1 CA2258920 A1 CA 2258920A1
Authority
CA
Canada
Prior art keywords
hyaluronic acid
autocross
arthropathies
treatment
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002258920A
Other languages
French (fr)
Other versions
CA2258920C (en
Inventor
Davide Bellini
Annamaria Paparella
Michael O'regan
Lanfranco Callegaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fidia SpA
Original Assignee
Fidia S.P.A.
Davide Bellini
Annamaria Paparella
Michael O'regan
Lanfranco Callegaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia S.P.A., Davide Bellini, Annamaria Paparella, Michael O'regan, Lanfranco Callegaro filed Critical Fidia S.P.A.
Publication of CA2258920A1 publication Critical patent/CA2258920A1/en
Application granted granted Critical
Publication of CA2258920C publication Critical patent/CA2258920C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention relates to compositions containing an autocross-linked form of hyaluronic acid alone or as a first component in mixture with a second component noncross-linked hyaluronic acid, and possibly also in combination with another pharmacologically active substance. These compositions can be used in the treatment of arthropathies due to their unique viscoelastic properties.
CA002258920A 1996-06-21 1997-06-20 Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies Expired - Lifetime CA2258920C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96PD000163A IT1288290B1 (en) 1996-06-21 1996-06-21 SELF-LETICULATED HYALURONIC ACID AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ARTHROPATHIES
ITPD96A000163 1996-06-21
PCT/EP1997/003238 WO1997049412A1 (en) 1996-06-21 1997-06-20 Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies

Publications (2)

Publication Number Publication Date
CA2258920A1 true CA2258920A1 (en) 1997-12-31
CA2258920C CA2258920C (en) 2003-12-02

Family

ID=11391464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002258920A Expired - Lifetime CA2258920C (en) 1996-06-21 1997-06-20 Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies

Country Status (11)

Country Link
US (1) US6251876B1 (en)
EP (1) EP0954323B1 (en)
JP (1) JP2000512650A (en)
AT (1) ATE257386T1 (en)
AU (1) AU732979B2 (en)
CA (1) CA2258920C (en)
DE (1) DE69727158T2 (en)
ES (1) ES2214628T3 (en)
HK (1) HK1024865A1 (en)
IT (1) IT1288290B1 (en)
WO (1) WO1997049412A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221854B1 (en) * 1996-03-05 2001-04-24 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
IT1296689B1 (en) * 1997-11-06 1999-07-14 Fidia Advanced Biopolymers Srl ESTERE DERIVATIVES OF HYALURONIC ACID HAVING VISCOELASTIC PROPERTIES AND THEIR USE IN THE BIOMEDICAL-HEALTH FIELD
US6824793B1 (en) 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
NZ511545A (en) * 1998-11-10 2003-08-29 Denki Kagaku Kogyo Kk Hyaluronic acid gel, partly soluble in aqueous solution, and easily ejectable from injector and a process for the preparation thereof
IT1302534B1 (en) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR
JP2003089647A (en) * 1999-03-10 2003-03-28 Takada Seiyaku Kk Articular disease therapeutic agent
DE60012557T2 (en) * 1999-10-15 2005-08-04 Genetics Institute, LLC, Cambridge HYALURONIC ACID COMPOSITIONS FOR THE DISPOSAL OF OSTEOGENIC PROTEINS
EP1481695A1 (en) * 1999-10-15 2004-12-01 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US7014860B1 (en) * 2000-02-03 2006-03-21 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid gel, process for producing the same, and medical material containing the same
US6638312B2 (en) * 2000-08-04 2003-10-28 Depuy Orthopaedics, Inc. Reinforced small intestinal submucosa (SIS)
US8366787B2 (en) 2000-08-04 2013-02-05 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP2005515802A (en) * 2001-07-16 2005-06-02 デピュイ・プロダクツ・インコーポレイテッド Hybrid / Synthetic Porous Extracellular Matrix Support Skeleton
US8025896B2 (en) 2001-07-16 2011-09-27 Depuy Products, Inc. Porous extracellular matrix scaffold and method
US7361195B2 (en) * 2001-07-16 2008-04-22 Depuy Products, Inc. Cartilage repair apparatus and method
US7819918B2 (en) 2001-07-16 2010-10-26 Depuy Products, Inc. Implantable tissue repair device
EP1416888A4 (en) 2001-07-16 2007-04-25 Depuy Products Inc Meniscus regeneration device and method
US20030033021A1 (en) 2001-07-16 2003-02-13 Plouhar Pamela Lynn Cartilage repair and regeneration scaffold and method
JP4197158B2 (en) 2001-07-16 2008-12-17 デピュイ・プロダクツ・インコーポレイテッド Devices with naturally occurring biologically derived materials
US7201917B2 (en) * 2001-07-16 2007-04-10 Depuy Products, Inc. Porous delivery scaffold and method
WO2003084571A1 (en) * 2002-04-08 2003-10-16 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
EP1507543A4 (en) * 2002-05-09 2006-07-26 Cambridgemed Inc A pharmaceutical composition for treatment of wounds containing blood plasma or serum
EA008354B1 (en) 2002-05-17 2007-04-27 Уайз Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
US20040166169A1 (en) * 2002-07-15 2004-08-26 Prasanna Malaviya Porous extracellular matrix scaffold and method
US20060135469A1 (en) 2002-08-16 2006-06-22 Denki Kagaku Kogyo Kabushiki Kaisha Separate type medical material
US8138265B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en) * 2004-01-08 2008-12-16 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US6982298B2 (en) * 2003-01-10 2006-01-03 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US20040185022A1 (en) * 2003-02-19 2004-09-23 Steven Rubin Regimen for acne treatment
US20040167480A1 (en) * 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20120283232A9 (en) * 2003-11-12 2012-11-08 Zhengjun Wang Process for making a pharmaceutical composition
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
US8524213B2 (en) 2003-12-30 2013-09-03 Genzyme Corporation Polymeric materials, their preparation and use
US20050226936A1 (en) * 2004-04-08 2005-10-13 Q-Med Ab Method of soft tissue augmentation
US7569233B2 (en) * 2004-05-04 2009-08-04 Depuy Products, Inc. Hybrid biologic-synthetic bioabsorbable scaffolds
US8017394B2 (en) * 2004-10-01 2011-09-13 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US7513866B2 (en) * 2004-10-29 2009-04-07 Depuy Products, Inc. Intestine processing device and associated method
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2249891B1 (en) 2008-02-13 2016-05-25 The Cleveland Clinic Foundation Molecular enhancement of extracellular matrix and methods of use
EP2300042A4 (en) * 2008-04-30 2012-05-02 Cleveland Clinic Foundation Compositions and methods to treat urinary incontinence
IT1395392B1 (en) 2009-08-27 2012-09-14 Fidia Farmaceutici VISCOELASTIC FROSTS LIKE NEW FILLERS
JP6215354B2 (en) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ， インコーポレイテッド Pharmaceutical formulations containing insoluble corticosteroids and soluble corticosteroids
TWI674899B (en) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 Pharmaceutical formulation
IT201900021693A1 (en) * 2019-11-20 2021-05-20 Bmg Pharma S P A BUTYRATED OR BUTYRATED DERIVATIVES AND FORMS OF CROSS-LINKED HYALURONIC ACID AND THEIR CROSS-LINKING PROCEDURE
EP4335876A1 (en) 2022-09-06 2024-03-13 Scivision Biotech Inc. Method of manufacturing auto-crosslinked hyaluronic acid gel and products thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219587B (en) * 1988-05-13 1990-05-18 Fidia Farmaceutici SELF-CROSS-LINKED CARBOXYLY POLYSACCHARIDES
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses

Also Published As

Publication number Publication date
CA2258920C (en) 2003-12-02
DE69727158T2 (en) 2004-11-11
HK1024865A1 (en) 2000-10-27
DE69727158D1 (en) 2004-02-12
EP0954323B1 (en) 2004-01-07
ATE257386T1 (en) 2004-01-15
JP2000512650A (en) 2000-09-26
IT1288290B1 (en) 1998-09-11
AU3435497A (en) 1998-01-14
WO1997049412A1 (en) 1997-12-31
ES2214628T3 (en) 2004-09-16
ITPD960163A1 (en) 1997-12-21
AU732979B2 (en) 2001-05-03
US6251876B1 (en) 2001-06-26
EP0954323A1 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
CA2258920A1 (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
CA2239174A1 (en) Novel compounds with analgesic effect
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
CA2338358A1 (en) Compounds and compositions for delivering active agents
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
AU3912493A (en) A pharmaceutical composition containing a defined lipid system
CA2274074A1 (en) Novel compounds with analgesic effect
FI973828A (en) Compounds and compositions for administering the active ingredients
EP0783299A4 (en) Compounds and compositions for delivering active agents
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
CA2172616A1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
CA2343130A1 (en) Cosmetic composition
CA2284774A1 (en) Theobromine antitussive compositions
CA2139725A1 (en) Endoparasiticidal compositions
EP1167354A3 (en) Racemic huperzine A
CA2286756A1 (en) Use of zinc hyaluronate against peptic ulcer
CA2031817A1 (en) Use of thrombospondin to promote wound healing
CA2285242A1 (en) Mixture of primary fatty acids obtained from sugar cane wax
CA2092505A1 (en) Pharmaceutical compositions containing l-carnitine or an acyl l-carnitine in combination with an ace-inhibitor for the treatment of cardiovascular disorders and a method for treating cardiovascular disorders
CA2272880A1 (en) Composition and method for reducing stinging in skin
AU5326598A (en) New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them
CA2263846A1 (en) Novel pyranoside derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170620